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Abstract
Objectives A minority of NSCLC patients benefit from anti-PD1 immune checkpoint inhibitors. A rational combination of 
biomarkers is needed. The objective was to determine the predictive value of tumor mutational load (TML),  CD8+ T cell 
infiltration, HLA class-I and PD-L1 expression in the tumor.
Materials and methods Metastatic NSCLC patients were prospectively included in an immune-monitoring trial (NTR7015) 
between April 2016-August 2017, retrospectively analyzed in FFPE tissue for TML (NGS: 409 cancer-related-genes) and by 
IHC staining to score PD-L1,  CD8+ T cell infiltration, HLA class-I. PFS (RECISTv1.1) and OS were analyzed by Kaplan–
Meier methodology.
Results 30 patients with adenocarcinoma (67%) or squamous cell carcinoma (33%) were included. High TML was associated 
with better PFS (p = 0.004) and OS (p = 0.025). Interaction analyses revealed that patients with both high TML and high total 
 CD8+ T cell infiltrate (p = 0.023) or no loss of HLA class-I (p = 0.026), patients with high total  CD8+ T cell infiltrate and 
no loss of HLA class-I (p = 0.041) or patients with both high PD-L1 and high TML (p = 0.003) or no loss of HLA class-I 
(p = 0.032) were significantly associated with better PFS. Unsupervised cluster analysis based on these markers revealed three 
sub-clusters, of which cluster-1A was overrepresented by patients with progressive disease (15 out of 16), with significant 
effect on PFS (p = 0.007).
Conclusion This proof-of-concept study suggests that a combination of PD-L1 expression, TML,  CD8+ T cell infiltration 
and HLA class-I functions as a better predictive biomarker for response to anti-PD-1 immunotherapy. Consequently, refine-
ment of this set of biomarkers and validation in a larger set of patients is warranted.
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Abbreviations
APM  Antigen processing machinery
CR  Complete response
FFPE  Formalin-fixed, paraffin-embedded
ICI  Immune checkpoint inhibitor
NGS  Next-genome sequencing
NSCLC  Non-small-cell lung cancer
PD  Progressive disease
PR  Partial response
SD  Stable disease
TML  Tumor mutational load
TPS  Tumor proportion score
Introduction
Tumors evade T-cell mediated destruction by exploiting 
inhibitory immune checkpoints such as the PD-1/ PD-L1 
pathway. The efficacy of treatment with immune checkpoint 
inhibitors (ICIs) targeting this pathway in non–small-cell 
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lung cancer (NSCLC) is limited, and better use of biomark-
ers is needed to predict response to treatment [3].
The currently most widely used biomarker is PD-L1 
expression in the tumor, as assessed by the PD-L1 tumor 
proportion score (TPS), which is positively associated with 
a response to ICI treatment in metastatic NSCLC patients 
[4]. However, the performance of the PD-L1 assay to predict 
clinical response remains poor [5].
The presence of tumor-infiltrating  CD8+ T cells which 
recognize tumor antigens, when presented at the tumor cell 
surface in the context of HLA class I, is a prerequisite for 
successful ICI treatment. A surrogate marker for recogni-
tion of tumor antigens is tumor mutational load (TML), a 
measurement of the frequency of mutations in tumor cells, 
that correlates with the number of neoantigens that can be 
recognized by  CD8+ T cells [6]. Next-generation genome 
sequencing (NGS) panels composed of about 300–600 can-
cer-related genes are designed to predict the TML with simi-
lar accuracy as whole-exome sequencing [7]. A strong  CD8+ 
type 1 T cell infiltration of tumors critically contributes to 
a better clinical outcome in cancer, including NSCLC [6]. 
Conversely, (partial) loss of HLA occurs in a sizeable frac-
tion of NSCLC tumors, as well as HLA diversity modulate 
the prognostic impact of tumor-infiltrating  CD8+ T cells, 
and thus survival after checkpoint blockade [8–11]. While 
TML is an emerging biomarker,  CD8+ T cell infiltration 
and HLA expression have not been considered as predictive 
biomarkers in NSCLC.
Therefore, this study is the first to determine the pre-
dictive value of the TML,  CD8+ T cells and HLA class I 




Patients with stage IV NSCLC who started nivolumab 
monotherapy between April 2016 and August 2017 at the 
Erasmus University Medical Center, Rotterdam, The Neth-
erlands, were included prospectively in the MULTOMAB 
study (Dutch Trial Registry NTR7015/NL6828). The study 
was approved by the independent ethics committee (Medical 
Research Ethics Committee Erasmus MC; MEC 16-011) and 
all patients provided written informed consent. Patients were 
randomly selected and assessed for eligibility. Patients with 
NSCLC stage IV were included who had been treated with 
nivolumab monotherapy (weight-based dosing: 3 mg/kg i.v., 
Q2W) and who were evaluable by RECIST v1.1. Patients 
who were treated with a prior line of immunotherapy were 
excluded. The median follow-up time was 27 weeks (inter-
quartile range 14–46 weeks) and the median time between 
the diagnostic biopsy and first administration of nivolumab 
was 5 weeks (interquartile range 1–41 weeks). The use of 
archival formalin-fixed, paraffin-embedded (FFPE) samples 
was in accordance with guidelines from the Dutch Federa-
tion of Medical Research and was approved by the inde-
pendent ethics committee (Medical Research Ethics Com-
mittee Erasmus MC; MEC 17-1186). Specimen handling 
and all biomarker assay analyses were undertaken blinded; 
a unique code was assigned for each patient, with a separate 
list linking these codes with the patient characteristics and 
outcomes.
TML assay
Mutational load was determined by the Oncomine TML 
assay (ThermoFisher Scientific, Waltham, MA) according 
to manufacturer’s protocol on an Ion Torrent S5 XL next-
generation sequencing platform (Gilford, NH). Mutational 
load is defined as the number of somatic nonsynonymous 
variants (missense and nonsense single nucleotide variants 
plus insertions and deletions) detected per megabase of 
exonic sequence with sufficient coverage. Germline vari-
ants were filtered out using the Mutation Load Calculation 
Filter Chain in Ion Reporter software 5.10 (ThermoFisher 
Scientific, Waltham, MA). A TML cut-off of 11 mut/Mb was 
used to differentiate between tumors with low or high TML.
Immunohistochemistry on FFPE samples
Expression patterns of classical HLA (HLA-A and HLA-
B/C) were assessed according to the Ruiter scoring system 
[12] as described before [10]. The intensity and percentage 
of cells in the tumor were determined based on the sum of 
the intensity of staining (ranging from 0–3) and percentage 
positive cells (ranging from 0–5). Loss of HLA class I was 
defined by a low Ruiter score (0–3) of both HLA-A and 
HLA-B/C. Patients were dichotomized for low or high total 
 CD8+ T cell infiltration based on the mean  CD8+ T cell infil-
tration for all patients and for low (< 50%) or high (≥ 50%) 
PD-L1 TPS (using the ready-to-use SP263 Ab clone on a 
Ventana Benchmark Ultra (both form Roche Diagnostics, 
Tucson, AZ) system according to the manufacturer’s instruc-
tions. Mouse monoclonal Abs HCA-2 and HC-10 (tissue 
culture supernatant respectively anti HLA-A, 1:500, and anti 
HLA-B/-C, 1:750; a generous gift from Prof. dr. J. Neefjes, 
Department of Cell and Chemical Biology, LUMC) were 
used to detect the free heavy chain of the classical HLA-A 
and HLA- B/-C molecule). The detection of  CD8+ T-cells 
was done using mouse monoclonal CD8 Ab (clone IA5, 
Leica Biosystems, Germany, 1:500). PD-L1 TPS was deter-
mined using clone SP263 (Ventana PD-L1 assay, Roche, 
Switzerland).
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Statistical analysis
Best overall response (BOR) was assessed according to 
RECIST v1.1 for complete response (CR), partial response 
(PR), stable disease (SD) and progressive disease (PD): min-
imum duration of 90 days for SD was required, confirmation 
of CR or PR was not necessary. PFS was defined as the time 
between the first administration of nivolumab until PD or 
death due to any cause, and OS until death due to any case. 
Survival was compared by log-rank test using Kaplan–Meier 
methodology. Group comparisons of categorical data were 
performed by 2-tailed χ2 or Fisher’s Exact test. Differences 
with two-sided P values < 0.05 were considered significant. 
No power analysis was performed in this proof-of-concept 
study. R version 1.1.453 (R-project, www.rproj ect.org) was 
used for hierarchical cluster analysis with complete linkage 
by Manhattan distance measure, using the mean for missing 
values, statistical software package SPSS v24.0.0.1 (SPSS, 
Chicago, USA) was used for further statistical analysis.
Results
A total of 99 patients were assessed for eligibility, of whom 
69 patients were excluded because of either insufficient or 
poor quality of samples (n = 33), or failure to obtain FFPE 
material from referring hospitals (n = 36). 30 patients were 
analyzed (Table 1). The mean duration of nivolumab treat-
ment was 5.4 months (SD: 4.6). Two patients (6%) devel-
oped severe immune-related toxicity (grade 3/4, according 
to CTCAE 4.03). All patients had at least one prior line of 
chemotherapy, consisting of platinum-based doublet chemo-
therapy, and three patients were also treated with an EGFR 
tyrosine kinase inhibitor. The mean duration of response to 
first-line chemotherapy was 7.2 months (SD: 4.7). Examples 
of two representative patients are shown in Fig. 1a, display-
ing TML and IHC staining of classical HLA,  CD8+ T cells 
and PD-L1.
First, the prognostic effect of each parameter on PFS 
(Fig. 2a–d) and OS (Fig. S1a-d) was determined. High TML 
was significantly associated with better PFS (p = 0.004) and 
OS (p = 0.025). PD-L1 was associated with improved PFS 
(p = 0.027), but not with OS (p = 0.121).  CD8+ T cells and 
HLA as individual biomarkers were not significantly asso-
ciated with better OS or PFS, which was expected [10], 
although normal expression of HLA class I resulted in the 
better OS and PFS when compared to complete or partial 
loss of HLA expression. Complete loss was defined by a 
low score (0–2), partial loss by an intermediate score (3–6), 
and normal expression by a high score (7–8). Patients with 
complete loss had impaired PFS compared to patients with 
partial loss or normal expression of HLA class I (Fig. S2).
However, interaction analyses between these two mark-
ers and the other markers revealed that each combination of 
two markers was significantly associated with better PFS 
(Fig. 2e–j), except for PD-L1 with  CD8+ T cells due to 
low power. Specifically, (1) high TML and either high total 
 CD8+ T cell infiltration (p = 0.023) or no loss of HLA class I 
(p = 0.026), (2) high total  CD8+ T cell infiltration and no loss 
of HLA class I (p = 0.041), and (3) high PD-L1 and either 
high TML (p = 0.003) or no loss of HLA class I (p = 0.032) 
was associated with better PFS.
Next, the patients were divided into two groups on the 
basis of a clinical response (CR/PR/SD) or failure to respond 
Table 1  Patient characteristics, TML and IHC patterns at baseline
From a total of 99 eligible patients, 69 were non-evaluable for this 
analysis, because either there was no sufficient archived FFPE tissue 
(n = 31), FFPE tissue could not be obtained from the referring hospi-
tal (n = 36) or the tissue was of poor quality (n = 2). The expression 
patterns of HLA-A and HLA-B/C as well as the total  CD8+ T cell 
infiltration in these patients were similar to what we reported before 
in a comparable group of NSCLC patients [10]
Patient characteristics Number Mean (SD)




























 Neg (0%) 11 (40.7)
 Pos (≥ 1%) 16 (59.3)
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(PD) to nivolumab treatment (Table S1). This revealed a 
significant overrepresentation of patients with a high TML 
(p = 0.043) and/or more profound total  CD8+ T cell infil-
tration (p = 0.005) among clinical responders. This associa-
tion was not found for HLA class I expression or PD-L1 
(TPS ≥ 1% or ≥ 50%).
A comparison of the absolute values for all these param-
eters confirmed that the mean TML (p = 0.001) and mean 
total  CD8+ T cell infiltrate (p = 0.004) were higher in the 
group of patients with a treatment response (Table S2). 
Notably, the TML was not directly correlated with  CD8+ 
T-cell infiltration or HLA expression but was positively 
associated with PD-L1 (p = 0.035; Table S3).
Finally, an unsupervised cluster analysis based on the 
four parameters was performed. This revealed two major 
clusters and a total of three sub-clusters (Fig. 1b). Cluster 
1A was overrepresented by patients with PD (15 out of 16) 
of which the tumors were negative for 2–3 of the 4 bio-
markers. Cluster 2 almost exclusively comprised patients 
with SD of which the tumor was positive for 2–3 biomark-
ers but did not express PD-L1. Survival analyses of the 
3 different clusters (Figs. 2k, S1k) indicate a significant 
effect on PFS (p = 0.007), while the OS (p = 0.74) was sig-
nificant in a post-hoc comparison of cluster 1A with 1B 
(p = 0.048).
Fig. 1  Patient examples and cluster analysis. a Example of two 
patients showing the BOR (RECIST v1.1): TML NGS output, and the 
IHC of HLA-A, HLA-B/C, total  CD8+ and PD-L1. For HLA, the per-
centage of positive tumor cells was classified (0–5) and the intensity 
of the staining (0–3), resulting in a final score based on both (0–8) 
and was categorized as 0–3 (low) or 4–8 (high); according to the 
Ruiter scoring system. Loss of classical HLA was defined as absent 
expression (0–3) of both HLA-A and HLA-B/C IHC. Magnifica-
tion × 20. b Heat map of unsupervised cluster analysis based on clas-
sical HLA, total CD8 tumor infiltration, TML and PD-L1 revealing 
three distinct clusters (1–3). BOR by RECIST v1.1 was incorporated 
in the heat map
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Discussion
The present proof-of-concept study suggests that in addition 
to PD-L1 expression also TML,  CD8+ T cell infiltration and 
HLA class I expression are associated with PFS and predict 
the response to anti-PD-1 immunotherapy. Interestingly, 
unsupervised cluster analysis of the patients based on all 
four markers revealed one cluster pattern that almost exclu-
sively identified non-responders (cluster 1A). In the current 
real-life setting, only a small amount of archival material 
could be used for TML determination and IHC staining, 
derived from routine biopsy specimens from the primary 
tumor and following initial diagnostic procedures (including 
routine NGS testing for driver mutations in some cases). We 
were able to demonstrate the clinical value of TML analysis 
in this immuno-oncology setting, and we believe this is the 
first study to do so in combination with a range of IHC bio-
markers in small, realistic biopsy specimens.
Our findings are consistent with previous studies in dif-
ferent settings, although those studies cannot be generalized. 
Associations between TMB and immune signatures are gen-
erally cancer type dependent [13], and it can be assumed 
that they are also tumor stage dependent. In addition, a 
prospective study in early-stage untreated NSCLC patients 
demonstrated a significant and independent association of 
low immune-evasion capacity (defined as tumors with no 
immune editing potential, no HLA loss and no antigen pro-
cessing machinery [APM] defects) and high number of neo-
antigens with increased disease-free survival [14].
Moreover, the release of checkpoint blockade by 
nivolumab may result in a series of dynamic changes in the 
composition of the tumor microenvironment [15] which 
override the current prediction (false negatives), but this 
was not taken into account as we were limited to the use of 
archival material prior to ICI therapy. Notably, a significant 
correlation between PD-L1 expression and TML was deter-
mined, which may contradict accumulating evidence from 
clinical trials [16]. This may be related to the limited number 
of patients, but may also result from the use of continuous 
covariates rather than stratified data in clinical trials where 
Fig. 2  PFS analysis. Kaplan–Meier plots showing the PFS by a TML 
high (> 11 mut/Mb) vs. low (< 11 mut/Mb), b  CD8+ T cell infiltration 
high vs. low, c PD-L1 high (> 50%) vs low, d classical HLA (-A and 
–B/C) loss vs. rest, e TML high and total  CD8+ high vs. rest, f TML 
high and no loss of classical HLA vs. rest, g total  CD8+ high and no 
loss of classical HLA vs. rest, h TML high and PD-L1 high vs. rest, i 
PD-L1 high and no loss of classical HLA vs. rest, j PD-L1 high and 
 CD8+ high vs. rest and k cluster (cluster 1A, 1B and 2)
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true correlations may easily be overlooked. Based on our 
findings, it could not be established that TML and PD-L1 
serve as an independent biomarker for clinical outcome.
An interesting finding of this study is the added value of 
expression of HLA class I molecules on cancer cells, which 
is known to be crucial for the recognition of tumor cells 
by CD8 + TCs. In our opinion, the actual detection of HLA 
class I expression is more valuable as a future biomarker 
for ICIs than genetic, epigenetic, transcriptional, post-tran-
scriptional or post-translational aberrations, such as loss 
of heterozygosity in HLA or B2M mutations, since protein 
expression is the ultimate outcome of all those changes. 
For instance, genetic studies have revealed that NLRC5, an 
HLA class I transactivator, is an important target for cancer 
immune evasion. The expression of NLRC5 correlated with 
that of HLA class I and negatively correlated with OS in 
stage III NSCLC [17]. We focused primarily on the expres-
sion of HLA class I and did not determine selective APM 
defects, while this could also affect the recognition of tumor 
antigens by the immune system. For HLA peptides to be 
presented to CD8 + T cells, peptides must be processed by 
proteolysis, trimmed by enzymes to fit into the groove of 
HLA molecules, and transported intracellularly by peptide 
transporters, endoplasmic reticulum chaperones and the 
Golgi apparatus. The antigen presenting pathway often is 
altered in cancer, including lung cancer [18, 19]. Further 
studies should be directed at investigating the impact of the 
APM defects on response to ICIs. Last but not least, due 
to the relatively low patient numbers, we decided to take 
complete loss defined as a low score (0–3) of both HLA-A 
and HLA-B/C, but not partial HLA class I loss into consid-
eration. However, a subgroup analysis showed that patients 
with complete loss have impaired OS and PFS compared to 
patients with no loss of HLA class I. The PFS of patients 
with partial loss was comparable to that of patients with no 
loss of HLA class I.
Taken together, the findings support the hypothesis that 
a rational combination of biomarkers—based on the bio-
logical requirements for the ICIs to work—may contribute 
to a more adequate response prediction of ICI treatment in 
NSCLC. Consequently, the refinement of this proposed set 
of biomarkers and validation in a greater set of patients is 
warranted.
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